X
<

Where Sanofi Stands after the 3Q17 Results

PART:
1 2 3 4 5 6 7 8
Part 7
Where Sanofi Stands after the 3Q17 Results PART 7 OF 8

Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17

Generics

Sanofi’s (SNY) general medicines and emerging markets businesses include established prescription products, generic products, and revenues from emerging markets. The generics business reported revenues of 433 million euros for 3Q17—a 0.9% YoY (year-over-year) fall.

The decline in revenues from generic products was driven by lower sales in European markets, which fell 7.1% YoY to 183 million euros, substantially offset by a 13.2% rise in US sales to 41 million euros, a 22.7% rise in revenues from rest of the world to 23 million euros, and nearly flat revenues from emerging markets at 186 million euros.

Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17

Interested in SNY? Don't miss the next report.

Receive e-mail alerts for new research on SNY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Consumer healthcare

Sanofi’s consumer healthcare business includes allergy, cough and cold products, pain management products, digestive products, and nutritional products. This business’s revenues rose 48.5% YoY at constant exchange rates to 1.13 billion euros in 3Q17. This revenue growth was driven by 17.6% growth in US sales to 241 million euros, 65.1% growth in revenues from European markets to 321 million euros, 37.5% growth in revenues from emerging markets to 411 million euros, and 150% growth in revenues from rest of the world to 159 million euros.

Pain products reported revenues of 309 million euros for 3Q17—a 50.5% YoY rise at constant exchange rates, driven by the strong performance of Doliprane and other pain management products.

Allergy, cough, and cold products reported revenues of 264 million euros for 3Q17, which was 52.8% higher YoY, driven by the strong performance of Allegra and Nasacort in international markets.

Digestive products reported revenues of 220 million euros for 3Q17, which was 97.4% higher YoY at constant exchange rates, driven by the strong performance of digestive products across all markets.

Nutritional products reported revenues of 162 million euros for 3Q17—38% higher YoY at constant exchange rates, driven by a strong performance in international markets.

Notably, the VanEck Vectors Pharmaceuticals ETF (PPH) has 4.6% of its total assets in Sanofi ADR (SNY), 5.1% in Perrigo (PRGO), 5.4% in Mylan NV (MYL), and 5.1% in Bristol-Myers Squibb (BMY).

X

Please select a profession that best describes you: